Tests an HIV vaccine in newborns exposed to HIV before birth
Tests an HIV vaccine in newborns born to mothers with HIV, who are uninfected.
Key facts
- Who runs it
- HIV Vaccine Trials Network
- Where
- Soweto, South AfricaSee the site
- Trial code
- Registry title
- Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 22 people, planned
- Starts
- 30 Mar 2027
- Expected to end
- 3 Jun 2027
- Type of study
- Interventional, 6 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- 426c.Mod.Core-C4b
- 3M-052-AF
- Aluminum hydroxide suspension (Alum)
- Placebo and Diluent
- Record updated
- 18 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for newborn babies, up to 7 days old, of mothers living with HIV who are on HIV treatment. The babies themselves must not have HIV.
- Age
- Infants up to 7 days old (the mother must be at least 18 years old).
- Sex
- All babies can join.
- Disease stage
- Mother: living with HIV, CD4 count of more than 350 cells/mcL, viral load of less than 400 copies/mL around delivery. Baby: born by Caesarean, at least 37 weeks, weight at birth at least 2.5 kg (6 lb).
- Earlier treatment
- Mother: has taken cART for at least 16 weeks before delivery and plans to continue it while breastfeeding. Baby: has started ARV prophylaxis. Mother: no earlier HIV vaccine or anti-HIV antibody prevention trial.
- Biomarker or test result
- Baby: negative HIV-1 nucleic acid test (NAT) on a sample taken within 72 hours of birth. Mother: confirmed HIV-1 positive.
Main reasons for not taking part
- Baby with a clinically significant birth defect
- Baby with a serious illness, an infection or a need for extra oxygen
- Baby who needs or may need blood products, immunoglobulin or immunosuppressive therapy
- Mother with detectable hepatitis B surface antigen (HBsAg)
- Mother or baby who received another investigational product
The registry criteria, word for word
Show all 35 criteriaShow less
Who can take part
- Mother's age is at least 18 years and is willing and able to provide written informed consent for their and their infant's participation in this study
- Mother is in the second or third trimester of singleton pregnancy, as determined by a clinical exam or sonography and reported menstrual history
- Mother agrees to donate umbilical cord blood
- Mother has a planned Caesarian delivery at Chris Hani Baragwanath Academic Hospital (Soweto) and plans to remain in the area after delivery and through study duration
- Mother is determined by the site investigator to be in good overall health at the time of delivery based on medical history and physical exam
- Mother has a documented CD4 count of more than 350 cells/mcL at screening
- Mother has been on cART for at least 16 weeks prior to delivery and intends to continue with cART for the duration of breastfeeding
- Mother has a viral load of less than 400 copies/mL between 2 weeks before and 7 days after delivery
- Mother has access to the participating HVTN CRS and is willing to be followed for the planned duration of the study
- Mother demonstrates understanding of this study and is able and willing to complete the informed consent process and delivery with verbal demonstration of understanding of all questionnaire items answered incorrectly
- Mother agrees not to enroll either self or infant in another research study for the duration of the trial without prior approval of the HVTN 316 PSRT
- Mother has confirmed positive HIV-1 status documented by medical records at any time during or prior to screening, and confirmed by the HVTN CRS by serology
- Born via Caesarean delivery to a pregnant woman living with HIV-1 who meets all maternal inclusion/exclusion criteria listed above
- Estimated gestational age at birth is at least 37 weeks; Note: If gestational age at birth is not documented in the infant's available birth records, study staff may assess gestational age at the earliest possible opportunity during the screening period and use this assessment for purposes of eligibility determination
- Weight at birth is at least 2.5 kg
- Has initiated ARV prophylaxis consistent with current site-specific standard of care
- Hemoglobin (HgB) more than 14.0 g/dL
- White blood cell (WBC) count ≥ 7,000 cells/mm3
- Platelets more than 100,000 cells/mm3
- Alanine aminotransferase (ALT) less than 1.25 times upper limit of age-adjusted normal
- Creatinine less than 1.1 times upper limit of age adjusted normal
- Negative HIV-1 nucleic acid test (NAT) on specimen drawn within 72 hours of birth
- Written informed consent provided by mother
- Age is equal to or less than 7 days
Who cannot take part
- Any World Health Organization (WHO) grade IV illness within 1 year prior to study enrollment, as determined by the history and physical examination and review of the medical record (if available). These include HIV wasting syndrome; PJP pneumonia; cerebral toxoplasmosis; extrapulmonary cryptococcosis; progressive multifocal leukoencephalopathy; any disseminated endemic mycosis (histoplasmosis); candidiasis of the esophagus, trachea, bronchi, or lung; disseminated atypical mycobacteria; non-typhoid salmonella septicemia; extrapulmonary tuberculosis; lymphoma; and Kaposi's sarcoma
- Prior participation in any HIV-1 vaccine or anti-HIV antibody-mediated prevention trial
- Receipt of any investigational agent during this pregnancy
- Receipt of blood products, immunoglobulin (Ig), or immunomodulating therapy within 45 days prior to, and the day of delivery
- Receipt of any other investigational product
- Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with or serve as a contraindication to protocol adherence, assessment of infant safety or reactogenicity, or a volunteer's ability to give informed consent
- Any condition that places the newborn at higher risk of early-onset sepsis, such as concern for active maternal infection at delivery, as determined by local site investigators (eg, fever)
- Detectable hepatitis B surface antigen (HBsAg)
- Documented or suspected serious medical illness, infection, clinically significant finding from physical examination, or immediate life-threatening condition, including requirement for ongoing supplemental oxygen, as judged by the examining clinician
- Receipt of or anticipated need for blood products, immunoglobulin, or immunosuppressive therapy. This includes infants who require hepatitis B immunoglobulin (HBIG), but it does not require exclusion of infants who receive hepatitis B vaccine in the newborn period
- Any clinically significant congenital anomaly/birth defect
Where in South Africa
- Soweto HVTN CRSSoweto, South AfricaContact: Fatima LaherNot yet recruiting
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety and immunogenicity of 426c.Mod.Core-C4b vaccine adjuvanted with 3M-052-AF + Alum in infants with perinatal HIV exposure who are without HIV at birth
The 6 groups in the trial
- Part A, Group 1: 426c.Mod.Core-C4b (20 mcg)Treatment being tested
Participants will receive 426c.Mod.Core-C4b (20 mcg) alone to be administered as two 0.25-mL intramuscular (IM) doses, one into each thigh at weeks 0, 12, and 28.
Treatment: 426c.Mod.Core-C4b
- Part A, Group 2: 426c.Mod.Core-C4b (20 mcg) + 3M-052-AF (0.3 mcg) + Alum (250 mcg)Treatment being tested
Participants will receive 426c.Mod.Core-C4b (20 mcg) admixed with 3M-052-AF (0.3 mcg) and aluminum hydroxide suspension (Alum) (250 mcg) to be administered as two 0.25-mL IM doses, one into each thigh at weeks 0, 12, and 28.
Treatment: 426c.Mod.Core-C4b, 3M-052-AF, and Aluminum hydroxide suspension (Alum)
- Part A, Group 3: 426c.Mod.Core-C4b (20 mcg) + 3M-052-AF (0.75 mcg) + Alum (250 mcg)Treatment being tested
Participants will receive 426c.Mod.Core-C4b (20 mcg) admixed with 3M-052-AF (0.75 mcg) and aluminum hydroxide suspension (Alum) (250 mcg) to be administered as two 0.25-mL IM doses, one into each thigh at weeks 0, 12, and 28.
Treatment: 426c.Mod.Core-C4b, 3M-052-AF, and Aluminum hydroxide suspension (Alum)
- Part A, Group 4: 426c.Mod.Core-C4b (20 mcg) + 3M-052-AF (1.5 mcg) + Alum (250 mcg)Treatment being tested
Participants will receive 426c.Mod.Core-C4b (20 mcg) admixed with 3M-052-AF (1.5 mcg) and aluminum hydroxide suspension (Alum) (250 mcg) to be administered as two 0.25-mL IM doses, one into each thigh at weeks 0, 12, and 28.
Treatment: 426c.Mod.Core-C4b, 3M-052-AF, and Aluminum hydroxide suspension (Alum)
- Part B, Group 5: 426c.Mod.Core-C4b (20 mcg) + 3M-052-AF (TBD)* + Alum (250 mcg)Existing treatment, for comparison
Participants will receive 426c.Mod.Core-C4b (20 mcg) admixed with 3M-052-AF (TBD) and Alum (250 mcg) to be administered as two 0.25-mL IM doses, one into each thigh at weeks 0, 12, and 28.
Treatment: 426c.Mod.Core-C4b, 3M-052-AF, and Aluminum hydroxide suspension (Alum)
- Part B, Group 6: PlaceboPlacebo, for comparison
Participants will receive Placebo (Tris Sodium Chloride (NaCl) buffer ) to be administered as two 0.25-mL IM doses, one into each thigh at weeks 0, 12, and 28.
Treatment: Placebo and Diluent
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Partially Randomized Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of 426c.Mod.Core-C4b Vaccine Adjuvanted With 3M-052-AF + Alum in Infants With Perinatal HIV Exposure Who Are Without HIV at Birth
- Plain-language title
- Tests an HIV vaccine in newborns exposed to HIV before birthGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 18 September 2026